Table 5. Resumption of in-person practice (n=421*).
| Question number and content | Categories | n (%) |
|---|---|---|
| Q53 Practice/institution caught up with cancellations/postponements | Yes | 190 (45.1) |
| No | 147 (34.9) | |
| Don’t know | 58 (13.8) | |
| Not applicable to my practice | 26 (6.2) | |
| Q54 Measures implemented to catch up with cancellations/postponements† | Allow longer workdays and/or working on weekends | 91 (21.6) |
| Increase availability of OR for treatment procedures | 91 (21.6) | |
| Convert OR procedures, if possible, to take place in clinics | 74 (17.6) | |
| Increase availability to labs for processing test samples | 48 (11.4) | |
| Other | 51 (11.9) | |
| Don’t know | 41 (9.7) | |
| Not applicable to my practice | 92 (21.9) | |
| Q55 Percentage of cancellations/postponements currently caught up with | 0% | 5 (1.2) |
| 1–24% | 60 (14.3) | |
| 25–49% | 98 (23.3) | |
| 50–74% | 72 (17.1) | |
| ≥75% | 88 (20.9) | |
| Don’t know | 55 (13.1) | |
| Not applicable to my practice | 43 (10.2) | |
| Q56 Patients attending routine screening at equivalent capacity to pre-COVID-19 era | Yes | 132 (31.4) |
| No | 216 (51.3) | |
| Don’t know | 52 (12.4) | |
| Not applicable to my practice | 21 (5.0) | |
| Q57 Percentage of patients attending routine screening compared to pre-COVID-19 | 0% | 3 (0.7) |
| 1–24% | 75 (17.8) | |
| 25–49% | 123 (29.2) | |
| 50–74% | 89 (21.1) | |
| ≥75% | 76 (18.1) | |
| Don’t know | 35 (8.3) | |
| Not applicable to my practice | 20 (4.8) | |
| Q58 Increase in frequency of patients with worsening of symptoms during screening | Yes | 136 (32.3) |
| No | 216 (51.3) | |
| Don’t know | 47 (11.2) | |
| Not applicable to my practice | 22 (5.2) | |
| Q59 Percentage of patients diagnosed with more advanced cytological abnormalities/lesions, in comparison to pre-COVID-19 | 0% | 98 (23.3) |
| 1–24% | 94 (22.3) | |
| 25–49% | 70 (16.6) | |
| 50–74% | 42 (10.0) | |
| ≥75% | 6 (1.4) | |
| Don’t know | 95 (22.6) | |
| Not applicable to my practice | 16 (3.8) | |
| Q60 Screening patients (with COVID-19) for cervical cancer | Yes | 113 (26.8) |
| No | 222 (52.7) | |
| Don’t know | 58 (13.8) | |
| Not applicable to my practice | 28 (6.7) |
*
Eighty-nine respondents did not answer; the total number of complete responses was used as the denominator.
†
Frequency count exceeded number of respondents (421) as some selected more than one answer.